Next Article in Journal / Special Issue
Increased Level of IFN-γ and IL-4 Spot-Forming Cells on ELISPOT Assay as Biomarkers for Acute Graft-Versus-Host Disease and Concurrent Infections
Previous Article in Journal / Special Issue
Cytomegalovirus (CMV)-Specific Perforin and Granzyme B ELISPOT Assays Detect Reactivation of CMV Infection in Inflammatory Bowel Disease
Cells 2012, 1(2), 51-60; doi:10.3390/cells1020051
Article

Characterization of Spontaneous Immune Responses against Long Peptides Derived from Bcl-X(L) in Cancer Patients Using Elispot

,
,
,
 and *
Received: 26 February 2012; in revised form: 7 March 2012 / Accepted: 3 April 2012 / Published: 26 April 2012
(This article belongs to the Special Issue ELISPOT Research)
View Full-Text   |   Download PDF [344 KB, uploaded 26 April 2012]   |   Browse Figures
Abstract: In recent years we and others have used the ELISPOT assay successfully to identify novel tumor antigens by the characterization of spontaneous HLA class I restricted immune responses against a number of minimal 9–10 amino acid long peptide epitopes. In the present study, we examined the capability of using longer peptides when scrutinizing Peripheral Blood Mononuclear Cells (PMBC) from melanoma patients for spontaneous immunity by means of ELISPOT IFN-γ secretion assay. To this end, we examined PBMC for the presence of specific T-cell responses against long peptides derived from the tumor associated antigen BCL-X(L). The protein product of the larger BCL-X(L) differs from Bcl-X(S) protein by an inserted region (amino acids 126–188). Thus, we scrutinized eight long peptides covering this inserted region for spontaneous immunity. The peptides were overlapping and consisted of 20–23 amino acids. PBMC were pre-stimulated with peptide-pulsed autologous dendritic cells (DC) and subjected to the IFN-γ ELISPOT assay. Four of the BCL-X(L) derived peptides elicited very frequent responses in several patients. Additionally, in all patients responses against more than one of the peptides could be detected. In conclusion several long BCL-X(L) derived peptide epitopes exist, which may be used in anti-cancer immunity. Furthermore, the ELISPOT assay offers an attractive and sensitive method for the characterization of spontaneous immune reactivity against long peptides.
Keywords: ELISPOT; Bcl-X(L); long peptides; antigen; T cells ELISPOT; Bcl-X(L); long peptides; antigen; T cells
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Larsen, S.K.; Hansen, M.; Svane, I.M.; Straten, P.T.; Andersen, M.H. Characterization of Spontaneous Immune Responses against Long Peptides Derived from Bcl-X(L) in Cancer Patients Using Elispot. Cells 2012, 1, 51-60.

AMA Style

Larsen SK, Hansen M, Svane IM, Straten PT, Andersen MH. Characterization of Spontaneous Immune Responses against Long Peptides Derived from Bcl-X(L) in Cancer Patients Using Elispot. Cells. 2012; 1(2):51-60.

Chicago/Turabian Style

Larsen, Stine Kiaer; Hansen, Morten; Svane, Inge Marie; Straten, Per Thor; Andersen, Mads Hald. 2012. "Characterization of Spontaneous Immune Responses against Long Peptides Derived from Bcl-X(L) in Cancer Patients Using Elispot." Cells 1, no. 2: 51-60.


Cells EISSN 2073-4409 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert